Imbria_Logo_Colour.png
Imbria Pharmaceuticals to Participate in the UBS Biotechnology Private Company Virtual Symposium
September 15, 2022 08:00 ET | Imbria Pharmaceuticals Inc.
BOSTON, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...
Imbria_Logo_Colour.png
Imbria Pharmaceuticals to Present Phase 2a Data from the Ninerafaxstat Program at the European Society of Cardiology Congress 2022
August 22, 2022 08:00 ET | Imbria Pharmaceuticals Inc.
BOSTON, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardio-metabolic company developing novel therapies designed to enhance cellular energetics, today...